The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

This latter finding is particularly noteworthy as unwanted GI impacts are generally the most commonly cited side effects of today's leading glucagon-like peptide-1 / glucose-dependent insulinotropic .

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...